Related Experiment Video
Updated: Jun 14, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
The biological treatment of renal-cell carcinoma and melanoma
1Medical Oncology at the Royal Free Hospital, London, UK.
Abstract:
Biological therapies are claiming a place in the routine management of some solid tumours. In this review we focus on the biological treatment of melanoma and renal-cell carcinoma, identifying the background to current practice and areas of promise that may be in routine clinical use in the near future. Melanomas and renal-cell carcinomas are particularly resistant to chemotherapy and radiotherapy and are characterised by the host immune response to the tumours. For this reason there has been particular interest in the biological therapy of these diseases. Biological therapies differ from chemotherapeutic approaches in their mechanism of action, time to response, and side-effect profiles. Although biological treatment has a long history, it is only with recent advances in immunology and molecular biology that progress has been made. In the next few years investigators expect to build on their research experience with biotherapeutic agents to provide tangible benefits for patients.
Insights
Biological therapies offer new hope for treating melanoma and renal-cell carcinoma. These treatments leverage the immune response, differing from traditional chemotherapy for better patient outcomes.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Solid tumors like melanoma and renal-cell carcinoma are often resistant to conventional treatments such as chemotherapy and radiotherapy.
- These cancers are characterized by the host's immune response, making them prime candidates for biological therapies.
Purpose of the Study:
- To review the current status and future potential of biological therapies for melanoma and renal-cell carcinoma.
- To highlight the unique mechanisms, response times, and side-effect profiles of biological treatments compared to chemotherapy.
Main Methods:
- Literature review focusing on biological treatments for melanoma and renal-cell carcinoma.
- Analysis of recent advances in immunology and molecular biology relevant to these therapies.
Main Results:
- Biological therapies are emerging as a significant treatment modality for specific solid tumors.
- Significant progress in biological treatment is attributed to recent advancements in immunology and molecular biology.
Conclusions:
- Biological therapies are poised to become a routine part of managing melanoma and renal-cell carcinoma.
- Further research and clinical experience with biotherapeutic agents are expected to yield substantial patient benefits in the near future.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy